2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.
Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine, Division of Hematology and Oncology, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer (mCRPC).
Genomic profiling is critical in men with prostate cancer, says Hussain. Germline and somatic testing could inform not only current treatment selection, but potential future options for patients.
For example, tissue-based testing can identify whether a patient harbors a targetable alteration, Hussain says. The results could inform whether a patient is a candidate for an approved PARP inhibitor or a clinical trial.
Additionally, early implementation of genetic testing could be important for blood relatives of men with prostate cancer, Hussain concludes.